Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis

Background: Ocrelizumab is an approved intravenously administered anti-CD20 antibody for multiple sclerosis (MS). Shortening the 600 mg infusion to 2 hours reduces the total site stay from 5.5–6 hours (approved infusion duration including mandatory pre-medication and post-infusion observation) to 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartung, H-P, Berger, T, Bermel, RA, Brochet, B, Carroll, WM, Holmøy, T, Karabudak, R, Killestein, J, Nos, C, Patti, F, Ross, A Perrin, Vanopdenbosch, L, Vollmer, T, Buffels, R, Garas, M, Kadner, K, Manfrini, M, Wang, Q, Freedman, MS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513877/
https://www.ncbi.nlm.nih.gov/pubmed/33039944
http://dx.doi.org/10.1016/j.msard.2020.102492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513877/
https://www.ncbi.nlm.nih.gov/pubmed/33039944
http://dx.doi.org/10.1016/j.msard.2020.102492

Ejemplares similares